Akero Therapeutics (AKRO) Competitors $45.54 -3.58 (-7.29%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$45.56 +0.02 (+0.04%) As of 03/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AKRO vs. ITCI, VTRS, MRNA, RDY, PCVX, SRPT, ASND, QGEN, ROIV, and TLXShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Ascendis Pharma A/S Qiagen Roivant Sciences Telix Pharmaceuticals Limited American Depositary Shares Akero Therapeutics (NASDAQ:AKRO) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has preferable earnings & valuation, AKRO or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Akero Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-12.14Intra-Cellular Therapies$680.50M20.51-$139.67M-$0.73-179.84 Which has more volatility & risk, AKRO or ITCI? Akero Therapeutics has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Is AKRO or ITCI more profitable? Akero Therapeutics has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Intra-Cellular Therapies -14.07%-9.93%-8.38% Does the MarketBeat Community believe in AKRO or ITCI? Intra-Cellular Therapies received 406 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 66.75% of users gave Intra-Cellular Therapies an outperform vote while only 65.17% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11665.17% Underperform Votes6234.83% Intra-Cellular TherapiesOutperform Votes52266.75% Underperform Votes26033.25% Does the media refer more to AKRO or ITCI? In the previous week, Intra-Cellular Therapies had 11 more articles in the media than Akero Therapeutics. MarketBeat recorded 26 mentions for Intra-Cellular Therapies and 15 mentions for Akero Therapeutics. Intra-Cellular Therapies' average media sentiment score of 0.49 beat Akero Therapeutics' score of 0.17 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Intra-Cellular Therapies 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of AKRO or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer AKRO or ITCI? Akero Therapeutics presently has a consensus price target of $76.29, indicating a potential upside of 67.51%. Intra-Cellular Therapies has a consensus price target of $106.08, indicating a potential downside of 19.20%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Akero Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 9 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.47 SummaryIntra-Cellular Therapies beats Akero Therapeutics on 12 of the 18 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-12.146.1524.9519.24Price / SalesN/A187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book4.746.447.334.28Net Income-$151.76M$139.03M$3.18B$247.04M7 Day Performance-8.19%-5.52%-4.42%-4.36%1 Month Performance-15.43%-8.56%-6.07%-5.60%1 Year Performance63.75%-14.59%11.42%3.38% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics4.1637 of 5 stars$45.54-7.3%$76.29+67.5%+63.8%$3.18BN/A-12.1430Earnings ReportAnalyst ForecastShort Interest ↑Gap DownITCIIntra-Cellular Therapies3.9068 of 5 stars$128.570.0%$106.08-17.5%+83.6%$13.67B$612.78M-147.78560Analyst ForecastShort Interest ↑Gap UpVTRSViatris3.5106 of 5 stars$11.39+1.2%$13.67+20.0%-25.9%$13.59B$15.43B-15.3938,000Earnings ReportMRNAModerna4.5045 of 5 stars$33.90-4.6%$60.63+78.9%-68.2%$13.05B$3.24B-3.655,600RDYDr. Reddy's Laboratories2.6284 of 5 stars$13.48+0.9%$17.00+26.2%-14.8%$11.25B$3.35B21.4627,048PCVXVaxcyte2.2214 of 5 stars$81.68+2.4%$127.71+56.4%+0.5%$10.18BN/A-17.76160Earnings ReportInsider TradeSRPTSarepta Therapeutics4.5719 of 5 stars$105.56-0.7%$176.77+67.5%-21.3%$10.08B$1.64B84.451,314ASNDAscendis Pharma A/S3.3354 of 5 stars$151.06-0.9%$200.21+32.5%-0.4%$9.17B$363.64M-21.28640QGENQiagen4.1881 of 5 stars$39.92+0.9%$47.71+19.5%-9.5%$8.86B$1.98B111.175,967Short Interest ↑Analyst RevisionROIVRoivant Sciences2.2614 of 5 stars$10.52-1.5%$18.08+71.9%-13.6%$7.51B$122.59M-70.13860TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$20.93+7.3%$22.00+5.1%N/A$7.05B$516.72M0.00N/AHigh Trading Volume Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Viatris Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Sarepta Therapeutics Alternatives Ascendis Pharma A/S Alternatives Qiagen Alternatives Roivant Sciences Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKRO) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts